Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 590-93-2 Chemical Structure| 590-93-2

Structure of 590-93-2

Chemical Structure| 590-93-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 590-93-2 ]

CAS No. :590-93-2
Formula : C4H4O2
M.W : 84.07
SMILES Code : CC#CC(O)=O
MDL No. :MFCD00004363
InChI Key :LUEHNHVFDCZTGL-UHFFFAOYSA-N
Pubchem ID :68535

Safety of [ 590-93-2 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H314-H290
Precautionary Statements:P501-P260-P234-P264-P280-P390-P303+P361+P353-P301+P330+P331-P363-P304+P340+P310-P305+P351+P338+P310-P406-P405
Class:8
UN#:3261
Packing Group:

Computational Chemistry of [ 590-93-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 6
Num. arom. heavy atoms 0
Fraction Csp3 0.25
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 21.28
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

37.3 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.98
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.78
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.17
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.38
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.19
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.42

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.85
Solubility 11.8 mg/ml ; 0.14 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.14
Solubility 6.04 mg/ml ; 0.0718 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.39
Solubility 204.0 mg/ml ; 2.43 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.26 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.78

Application In Synthesis of [ 590-93-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 590-93-2 ]

[ 590-93-2 ] Synthesis Path-Downstream   1~15

  • 1
  • [ 4401-71-2 ]
  • [ 590-93-2 ]
  • But-2-ynoic acid (4S,5S)-5-bromo-1,3,5-trimethyl-2,6-dioxo-hexahydro-pyrimidin-4-yl ester [ No CAS ]
  • 2
  • [ 6281-32-9 ]
  • [ 590-93-2 ]
  • [ 1234580-81-4 ]
  • 3
  • [ 590-93-2 ]
  • [ 119072-55-8 ]
  • [ 100-52-7 ]
  • [ 3468-18-6 ]
  • [ 1447525-13-4 ]
  • 4
  • [ 31739-56-7 ]
  • [ 590-93-2 ]
  • [ 119072-55-8 ]
  • [ 2393-23-9 ]
  • [ 1604835-43-9 ]
  • 5
  • [ 931-53-3 ]
  • [ 31739-56-7 ]
  • [ 590-93-2 ]
  • [ 2393-23-9 ]
  • [ 1604835-44-0 ]
  • 6
  • [ 31739-56-7 ]
  • [ 590-93-2 ]
  • [ 2769-64-4 ]
  • [ 2393-23-9 ]
  • [ 1604835-45-1 ]
  • 7
  • [ 31739-56-7 ]
  • [ 590-93-2 ]
  • [ 7175-47-5 ]
  • [ 2393-23-9 ]
  • [ 1604835-49-5 ]
  • 8
  • [ 31739-56-7 ]
  • [ 590-93-2 ]
  • [ 119072-55-8 ]
  • [ 5763-61-1 ]
  • [ 1604835-46-2 ]
  • 9
  • [ 2620-50-0 ]
  • [ 931-53-3 ]
  • [ 31739-56-7 ]
  • [ 590-93-2 ]
  • [ 1604835-47-3 ]
  • 10
  • [ 590-93-2 ]
  • [ 37585-16-3 ]
  • C11H8ClNO2 [ No CAS ]
  • 11
  • [ 590-93-2 ]
  • [ 1420478-90-5 ]
  • [ 1420477-60-6 ]
YieldReaction ConditionsOperation in experiment
90% With triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In dichloromethane; at 20 - 30℃; for 3h; A mixture of compound XI (4.14 g, 10 mmol) , compound IV (2.66 g, 11 mmol), dioxane (34 mL) and K2CO3 aqueous solution (4.14 g K2CO3 in 15 mL water) was added Pd(dppf)Cl2 (73 mg, 0.1 mmol) under nitrogen. The mixture was stirred for 3 h at 90~100 C. The organic phase was separated and concentrated. The residue was purified by silica gel column chromatography using heptane/EtOAc to afford compound XII (4.9 g, 92% yield). (0115) To a round-bottom flask was added compound XII (2.4 g), acetic acid (12 mL) and HBr (33% in acetic acid, 12 mL). The mixture was stirred for 2 h at 20~30 C. Water (300 mL) and DCM (100 mL) was added. The aqueous phase was separated and washed with DCM (100 mL). The aqueous phase was adjusted to pH > 10 with 30% NaOH aqueous solution and extracted with DCM (150 mL). The DCM phase was concentrated to give compound XII I (1.64 g, 91% yield). To a round-bottom flask was added compound XIII (0.50 g, 1.25 mmol), 2-butynoic acid (0.11 g, 1.31 mmol), HATU (0.48 g, 1.25 mmol), DCM (10 mL) and triethylamine (0.50 g, 5 mmol). The mixture was stirred for 3 h at 20~30 C. The reaction mixture was washed with water (5 mL) and concentrated. The residue was purified by silica gel column chromatography using DCM/MeOH to afford compound XV (0.5 g, 90% yield). (0116) XH NMR (400 MHz, DMSO) delta 10.82 (s, 1H), 8.42 - 8.39 (m, 1H), 8.26 - 8.15 (m, 3H), 7.90 - 7.73 (m, 4H), 7.21 - 7.11 (m, 2H), 6.25 - 6.05 (m, 2H), 5.75 - 5.40 (m, 1H), 3.90 - 3.55 (m, 2H), 2.47 - 2.20 (m, 2H), 2.20 - 2.10 (m, 1H), 2.07 - 1.90 (m, 3H), 1.63 (s, 1H).
74% With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; triethylamine; In dichloromethane;Large scale; 4-{ 8-Amino-3-[(2S)-2-pyrrolidinyl]imidazo[l,5-a]pyrazin-l-yl}-/V-(2-pyridinyl)- benzamide (Compound (VII), 131.7 kg, 1.0 mol. eq.) was slurried in dichloromethane (955 L, 7.25 rel. vol.) and triethylamine (90.1 kg, 2.7 mol. eq.). 2-butynoic acid (33.3 kg, 1.2 mol. eq.) in dichloromethane (263.4 L, 2.0 rel. vol.) was added, followed by l-propylphosphonic acid anhydride (T3P) (50%w/w solution in dichloromethane, 209.8 kg, 1.0 mol. eq.). The resulting organic solution of the product was washed twice with water (658.5 L, 5.0 rel. vol.) and then water (1317 L, 10.0 rel. vol.) was added. The mixture was then acidified using 6M aqueous hydrochloric acid to approximately pH 2.2 and then 2M aqueous hydrochloric acid added to reach a pH of 1.8 to 2.2 before separating the organic phase, which was discarded. Dichloromethane (1317 L, 10.0 rel. vol.) was added to the aqueous phase and the mixture is adjusted to a pH of 4.5 to 5.0 with triethylamine. The organic phase was separated off and the aqueous phase was re-extracted with dichloromethane (527 L, 4.0 rel. vol.). The combined dichloromethane extracts were screened and the organic phase was concentrated to approximately 5.0 rel. vol. Ethanol (1712 L, 13.0 rel. vol.) was added and the mixture distilled (at about 360 mbar) maintaining a constant volume (of 18.0 rel. vol.) by the addition of ethanol (1580 L, 12.0 rel. vol.). A portion of crystalline 4-{8-amino- 3-[(2S)-l-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[l,5-a]pyrazin-l-yl}-/V-(pyridin-2-yl)benzamide (Compound (VIII), 1.32 kg, 0.01 rel. wt.) was added as seed, and the solution held at 50C for 10 hours to crystallize the product. The mixture was then cooled over 7 hours and filtered. The product was washed twice with ethanol (527 L, 4.0 rel. vol.) and then dried at 50C under vacuum to yield a white crystalline solid acalabrutinib (Compound VIII, 113.6 kg, 74%). (0440) [00228] This compound exists as a mixture of conformers in solution and resonances are quoted for the major conformer only. 1H NMR (500 MHz, DMSO-d6) d 1.95-2.02 (m, 4H), 2.09- 2.15 (m, 1H), 2.23-2.38 (m, 2H), 3.81 (t, J = 6.7 Hz, 2H), 5.47 (dd, J = 7.6, 4.3 Hz, 1H), 6.13 (br s, 2H), 7.11 (d, J = 5.1 Hz, 1H), 7.17 (ddd, J = 7.4, 4.8, 0.8 Hz, 1H), 7.70-7.73 (m, 2H), 7.78 (d, J = 5.1 Hz, 1H), 7.82-7.87 (m, 1H), 8.13-8.16 (m, 2H), 8.20-8.23 (m, 1H), 8.39 (ddd, J = 4.8, 1.9, 0.8 Hz, 1H), 10.83 (s, 1H). 13C NMR (126 MHz, DMSO-d6) d 3.3, 23.9, 31.2, 48.2, 51.3, 74.3, 88.3, 107.0, 113.8, 114.7, 119.8, 127.9, 128.3, 129.0, 132.7, 133.2, 137.9, 138.1, 141.0, 148.0, 151.4, 151.8, 152.2, 165.7.
72% With 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide; In dichloromethane; at -15 - 5℃; for 3h; A clear, yellow solution of 2-butynoic acid (7) (42 mg, 0.50 mmol), /V-hydroxysuccinimide (58 mg, 0.50 mmol) and the compound of Formula (5- A) (200 mg, 0.50 mmol) in dichloromethane (6 mL) was cooled to -15 to -10 C. A solution of DCC (103 mg, 0.50 mmol) in dichloromethane (1 mL) was added dropwise to the reaction solution over a period of 15 minutes followed by warming the solution to 0-5 C. A slight suspension was formed after a period of 1 hour. The reaction was deemed complete after 2 hours by1H- NMR (consumption of the compound of Formula (5-A)). The reaction suspension was warmed to room temperature and filtered to remove the DCU by-product. The cake was washed with dichloromethane (2 x 2 mL) and the filtrate was washed with water (1 x 3 mL). The organic layer was then separated, dried over anhydrous sodium sulfate, and concentrated in vacuo at 30-35 C to afford a crude product as a yellow solid (0.31 g). The solid was then purified by column chromatography using ethyl acetate and methanol to afford Acalabrutinib (1 ) as a yellow solid (0.17 g, 0.36 mmol, 72% yield).
18% With triethylamine; HATU; In dichloromethane; at 20℃; for 0.5h; (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N- (pyridin-2-yl)benzamide was made from (S)-4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1 ,5- a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide and 2-butynoic acid as follows. To a solution of (S)- 4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide (19.7 mg, 0.049 mmol), triethylamine (20 mg, 0.197 mmol, 0.027 mL) 2-butynoic acid (4.12 mg, 0.049 mmol) in dichloromethane (2 mL) was added HATU (18.75 mg, 0.049 mmol). The mixture was stirred for 30 min at room temperature. The mixture was washed with water dried over magnesium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC. Fractions containing product were collected and reduced to dryness to afford the title compound (10.5 mg, 18.0%).
18% With triethylamine; HATU; In dichloromethane; at 20℃; for 0.5h; (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N- (pyridin-2-yl)benzamide was made from (S)-4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1 ,5- a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide and 2-butynoic acid as follows. To a solution of (S)- 4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide (19.7 mg, 0.049 mmol), triethylamine (20 mg, 0.197 mmol, 0.027 mL) 2-butynoic acid (4.12 mg, 0.049 mmol) in dichloromethane (2 mL) was added HATU (18.75 mg, 0.049 mmol). The mixture was stirred for 30 min at room temperature. The mixture was washed with water dried over magnesium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC. Fractions containing product were collected and reduced to dryness to afford the title compound (10.5 mg, 18.0%).
18% With triethylamine; HATU; In dichloromethane; at 20℃; for 0.5h; (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N- (pyridin-2-yl)benzamide was made from (S)-4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1 ,5- a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide and 2-butynoic acid as follows. To a solution of (S)- 4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide (19.7 mg, 0.049 mmol), triethylamine (20 mg, 0.197 mmol, 0.027 mL) 2-butynoic acid (4.12 mg, 0.049 mmol) in dichloromethane (2 mL) was added HATU (18.75 mg, 0.049 mmol). The mixture was stirred for 30 min at room temperature. The mixture was washed with water dried over magnesium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC. Fractions containing product were collected and reduced to dryness to afford the title compound (10.5 mg, 18.0%).
219 g With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; To a mixture of (S)-4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[l,5-alpyrazin-l-yl)-N- (pyridin-2-yl)benzamide (300 g), 2-butynoic acid (82.1 g), dichloromethane (6000 mL), 1- ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (201.5 g) was added and reaction mixture was stirred at ambient temperature for 4 - 5 hours. Water (3000 mL) and isopropanol (1500 mL) was added to reaction mixture and stirred for 10-15 minutes at ambient temperature followed by layer separation. Lower organic layer was concentrated followed by addition of methanol (450 mL) and concentrated. Resulting residue was stirred in water (525 mL) and methanol (2250 mL) at 60-65 C for 30-40 minutes, treated with activated carbon and filtered. Water (625 mL) was added to combined filtrate and stirred at ambient temperature for 15-16 hours. The reaction mixture was cooled at 0-5 C and stirred for 1-2 hours. The resulting product was filtered, washed with methanol: water (1:1, 300 mL) and dried to give 219 g of Acalabrutinib with purity of 99.5% by HPLC.

  • 12
  • [ 590-93-2 ]
  • [ 37585-16-3 ]
  • C11H10ClNO2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With dicyclohexyl-carbodiimide; In dichloromethane; at 20℃; General procedure: To a solution of but-2-ynoic acid (8 mmol, 1 equiv) and 2-aminobenzylalcohol (8 mmol, 1 equiv) in CH2Cl2 (60 mL) at 0 C was added a solution of N,N?-dicyclohexylcarbodiimide (DCC) (8 mmol, 1 equiv) in CH2Cl2 (20 mL) dropwise. The mixture was stirred at room temperature overnight, and then filtrated through a short pad of celite. The filtrate was concentrated and used for the next step without further purication. The crude solid was added to a suspension of pyridinium chlorochromate (PCC) (1.5-2.0equiv) and celite in CH2Cl2 (80 mL). The mixture was stirred at room temperature for 1-4 h, then filtrated and puried by silica gel column chromatography to give the product. The above crude solid was dissolved in THF (50 mL) and was added to a solution of NaH (1.3 equiv.) in THF (20 mL) dropwise at 0 C. The mixture was stirred at 0 C for half an hour, then MeI (1.3 equiv.) was added. The reaction mixture was stirred at room temperature until completion as monitored by TLC and then quenched by addition of saturated aqueous NH4Cl solution. The mixture was extracted with EtOAc, and the organic layer was washed with H2O and brine, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was puried by column chromatography on silica gel (eluent: ethyl acetate/petroleum ether = 1/4) to afford products 1b-1g.
  • 13
  • [ 590-93-2 ]
  • [ 15980-22-0 ]
  • N-(4-hydroxy-3,5-dimethylphenyl)but-2-ynamide [ No CAS ]
  • 14
  • [ 590-93-2 ]
  • C22H21N7O*3ClH [ No CAS ]
  • [ 1420477-60-6 ]
YieldReaction ConditionsOperation in experiment
78% With 4-methyl-morpholine; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 25 - 30℃; 10 (50.88 g, 100 mmol) and N,N-dimethylformamide (254 mL) were added to a three-neck flask.Stir well and cool to 0~5 C.Add butynoic acid (9.25 g, 110 mmol),Add EDCI (23.00g, 120mmol),N-methylmorpholine (40.46 g, 400 mmol) was added dropwise.After the addition, the reaction is carried out at 25 to 30 C for 6 to 8 hours.At the end of the reaction, water (254 mL) was added.Extracted 3 times with dichloromethane (127 mL),The combined organic phase 10% sodium bicarbonate solution (127 mL) was washed once.Wash twice with saturated saline (127 mL),Dry over anhydrous sodium sulfate,After concentration, beat with isopropyl alcohol petroleum ether mixed solvent,filter,The product was dried (36.31 g, 78%).
  • 15
  • [ 590-93-2 ]
  • [ 84539-22-0 ]
  • 4-(5-(prop-1-yn-1-yl)pyrimidin-2-yl)morpholine [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 590-93-2 ]

Alkynyls

Chemical Structure| 142-45-0

A151533 [142-45-0]

Acetylenedicarboxylic Acid

Similarity: 1.00

Chemical Structure| 5963-77-9

A107561 [5963-77-9]

Pent-2-ynoic acid

Similarity: 0.85

Chemical Structure| 762-42-5

A401572 [762-42-5]

Dimethyl but-2-ynedioate

Similarity: 0.77

Chemical Structure| 4341-76-8

A188953 [4341-76-8]

Ethyl 2-butynoate

Similarity: 0.71

Chemical Structure| 762-21-0

A958456 [762-21-0]

Diethyl acetylenedicarboxylate

Similarity: 0.71

Aliphatic Chain Hydrocarbons

Chemical Structure| 142-45-0

A151533 [142-45-0]

Acetylenedicarboxylic Acid

Similarity: 1.00

Chemical Structure| 5963-77-9

A107561 [5963-77-9]

Pent-2-ynoic acid

Similarity: 0.85

Chemical Structure| 762-42-5

A401572 [762-42-5]

Dimethyl but-2-ynedioate

Similarity: 0.77

Chemical Structure| 4341-76-8

A188953 [4341-76-8]

Ethyl 2-butynoate

Similarity: 0.71

Chemical Structure| 762-21-0

A958456 [762-21-0]

Diethyl acetylenedicarboxylate

Similarity: 0.71

Carboxylic Acids

Chemical Structure| 142-45-0

A151533 [142-45-0]

Acetylenedicarboxylic Acid

Similarity: 1.00

Chemical Structure| 5963-77-9

A107561 [5963-77-9]

Pent-2-ynoic acid

Similarity: 0.85

Chemical Structure| 79-14-1

A701706 [79-14-1]

2-Hydroxyacetic acid

Similarity: 0.56

Chemical Structure| 563-96-2

A432964 [563-96-2]

2,2-Dihydroxyacetic acid

Similarity: 0.53

Chemical Structure| 298-12-4

A521642 [298-12-4]

2-Oxoacetic acid

Similarity: 0.53